Johnson & Johnson acquires for $14.6 billion! Intra-Cellular Therapies stock surges nearly 38% in pre-market trading
I'm PortAI, I can summarize articles.
Johnson & Johnson acquired Intra-Cellular Therapies for $14.6 billion, making it the largest biotechnology merger and acquisition deal since 2023, and the first biopharmaceutical merger and acquisition exceeding $10 billion in 2024. Intra-Cellular's stock price rose nearly 38% in pre-market trading, while Johnson & Johnson's stock price remained unchanged
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments